Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TRVI
SellHot AirTrevi Therapeutics, Inc. · Healthcare · United States · $2.4B · Avg Vol: $24M/d
COMPANY DESCRIPTION
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic neurological conditions, particularly pruritus (itch) associated with liver and kidney diseases. Its lead candidate, Haduvio (nalbuphine ER), is an oral opioid modulator in late-stage development for pruritus in various indications. Trevi operates as a niche player, addressing significant unmet medical needs in underserved patient populations with chronic pruritic conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.19 | -0.14 | -0.47 | -0.32 | — | -0.35 | -0.48 | -0.58 | — |
| Shares | 142.0M | 142.0M | 93.6M | 128.3M | -9.6% | 142.5M | — | — | — |
| Debt | 9.2M | 1.3M | 1.0M | 0.8M | -56.5% | 0.6M | — | — | — |
| Equity | 107.5M | 82.5M | 99.6M | 183.2M | 19.5% | — | — | — | — |
| Op CF | -28.2M | -31.7M | -38.3M | -42.1M | — | -52.6M | — | — | — |
| Inv CF | -107.4M | 59.4M | -21.5M | -94.1M | — | — | — | — | — |
| Fin CF | 111.3M | -7.9M | 61.5M | 121.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TRVI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc.(you) | $2.4B | 28 | Sell |
| PGEN | Precigen, Inc. | $2.5B | 28 | Sell |
| NRIX | Nurix Therapeutics, Inc. | $2.7B | 28 | Sell |
| NUVB | Nuvation Bio Inc. | $2.3B | 31 | Sell |
| ZYME | Zymeworks Inc. | $2.0B | 28 | Sell |
| MBX | MBX Biosciences, Inc. | $3.0B | 28 | Sell |
| NKTR | Nektar Therapeutics | $2.5B | 23 | Sell |
| VIR | Vir Biotechnology, Inc. | $1.8B | 29 | Sell |
| ATAI | AtaiBeckley Inc. | $2.7B | 23 | Sell |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.8B | 24 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%